ArticleBlood advances2022
The incidence of cancer-associated thrombosis is increasing over time.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2025Pooled it
- Incidence and risk factors of VTE in lung cancer: a meta-analysis.Annals of medicine · 2024Pooled it
- Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism.Nature reviews. Cardiology · 2026Review
- DVT-primed neutrophils reshape the brain microenvironment to promote brain metastasis.bioRxiv : the preprint server for biology · 2026Article
- Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study.American journal of hematology · 2026Article
- No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.International journal of cancer · 2026Article
- Development and External Validation of a Postoperative Risk Score for Venous Thromboembolism in Epithelial Ovarian Cancer.The Kaohsiung journal of medical sciences · 2026Article
- A deep learning model to dynamically predict cancer-associated thromboembolism in large-scale healthcare systems.NPJ digital medicine · 2026Article
- Epidemiology of Cancer-Associated Venous Thromboembolism Across the United States.American journal of hematology · 2026Article
- Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Article
- Contemporary Challenges in Venous Thromboembolism: Evolving Populations and Implications for Management and Risk Stratification.Journal of clinical medicine · 2026Review
- Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026Review
- Extracellular Vesicles (EVs) Derived from Senescent Endothelial Cells Promote Platelet Activation.International journal of molecular sciences · 2026Article
- Trends and projections in cause-specific mortality among patients with colorectal cancer in the United States, 1999-2040.Frontiers in public health · 2026Article
- Nationally representative estimates of health care burden of venous thromboembolism in hospitalized cancer patients.Research and practice in thrombosis and haemostasis · 2026Article
- Thromboembolic disease and hemostatic alterations in tumor-bearing dogs - A narrative review.Frontiers in veterinary science · 2026Review
- Heterogeneity of thromboembolic risk across ALK inhibitors: a retrospective real-world study identifying crizotinib-specific signals and high-risk subpopulations.Frontiers in pharmacology · 2026Article
- Case Report: Perioperative management of ovarian cancer surgery in suspected trousseau's syndrome with recent ischemic stroke and acute myocardial injury.Frontiers in medicine · 2026Article
- Direct oral anticoagulants compared to low molecular weight heparin for the treatment of venous thromboembolism among individuals with gastrointestinal cancer: an updated meta-analysis.Thrombosis journal · 2025Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality for patients with malignancy and varies by primary cancer type, stage, and therapy. We aimed to characterize the incidence, risk factors, temporal trends, and the effect on mortality of CAT. The California Cancer Registry was linked to the statewide hospitalization database to identify individuals with the 13 most common malignancies diagnosed between 2005 and 2017 and determine the 6- and 12-month cumulative incidence of CAT by venous thromboembolism (VTE) location, tumor type, and stage after adjusting for competing risk of death. Cox proportional hazard regression models were used to determine risk factors associated with CAT and the effect of CAT on all-cause mortality. 942 019 patients with cancer were identified; 62 003 (6.6%) had an incident diagnosis of CAT. Patients with pancreatic, brain, ovarian, and lung cancer had the highest, and patients with breast and prostate cancer had the lowest 12-month cumulative incidence of CAT. For most malignancies, men, those with metastatic disease and more comorbidities, and African Americans (vs non-Hispanic Whites) were at highest risk for CAT. Patients diagnosed with cancer between 2014 and 2017 had a higher risk of CAT compared with those diagnosed between 2005 and 2007. CAT was associated with increased overall mortality for all malignancies (HR ranges 1.89 to 4.79). The incidence of CAT increased over time and was driven by an increase in pulmonary embolism±deep vein thrombosis (PE±DVT). CAT incidence varies based on tumor type and stage and on individual risk factors including gender, race/ethnicity, and comorbidities. For all tumor types, CAT is associated with an increased mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.